IRIS Accounts Production v24.3.2.46 11749031 Board of Directors 1.7.23 30.6.24 30.6.24 21/3/2025 0 0 false true false false true false Auditors Opinion Ordinary share capital 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh117490312023-06-30117490312024-06-30117490312023-07-012024-06-30117490312022-06-30117490312022-07-012023-06-30117490312023-06-3011749031ns15:EnglandWales2023-07-012024-06-3011749031ns14:USDollar2023-07-012024-06-3011749031ns10:Director12023-07-012024-06-3011749031ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3011749031ns10:SmallEntities2023-07-012024-06-3011749031ns10:Audited2023-07-012024-06-3011749031ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3011749031ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3011749031ns10:FullAccounts2023-07-012024-06-3011749031ns10:OrdinaryShareClass12023-07-012024-06-3011749031ns10:Director32023-07-012024-06-3011749031ns10:CompanySecretary12023-07-012024-06-3011749031ns10:RegisteredOffice2023-07-012024-06-3011749031ns5:CurrentFinancialInstruments2024-06-3011749031ns5:CurrentFinancialInstruments2023-06-3011749031ns5:ShareCapital2024-06-3011749031ns5:ShareCapital2023-06-3011749031ns5:RetainedEarningsAccumulatedLosses2024-06-3011749031ns5:RetainedEarningsAccumulatedLosses2023-06-3011749031ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3011749031ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-3011749031ns10:OrdinaryShareClass12024-06-3011749031ns5:RetainedEarningsAccumulatedLosses2023-06-3011749031ns5:RetainedEarningsAccumulatedLosses2023-07-012024-06-30
REGISTERED NUMBER: 11749031 (England and Wales)















Trucs Therapeutics Limited

Audited Financial Statements

for the Year Ended 30 June 2024






Trucs Therapeutics Limited (Registered number: 11749031)

Contents of the Financial Statements
for the year ended 30 June 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Trucs Therapeutics Limited

Company Information
for the year ended 30 June 2024







Directors: M Henry
G Wood





Secretary: M Henry





Registered office: 2 Minton Place
Victoria Road
Bicester
Oxfordshire
OX26 6QB





Registered number: 11749031 (England and Wales)





Auditors: Cooper Parry Group Limited
Statutory Auditor
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

Trucs Therapeutics Limited (Registered number: 11749031)

Balance Sheet
30 June 2024

2024 2023
Notes $ $
Current assets
Debtors 4 1,911,680 1,879,330
Cash at bank 328,226 451,756
2,239,906 2,331,086
Creditors
Amounts falling due within one year 5 26,178 62,085
Net current assets 2,213,728 2,269,001
Total assets less current liabilities 2,213,728 2,269,001

Capital and reserves
Called up share capital 6 121 121
Retained earnings 7 2,213,607 2,268,880
Shareholders' funds 2,213,728 2,269,001

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 March 2025 and were signed on its behalf by:





G Wood - Director


Trucs Therapeutics Limited (Registered number: 11749031)

Notes to the Financial Statements
for the year ended 30 June 2024


1. Statutory information

Trucs Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in US Dollars, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest $1.

Basis other than going concern
The directors concluded that the company is no longer a going concern. Accordingly these financial statements are prepared on a basis other than going concern.

This basis includes, where applicable, writing the company's assets down to net realisable value. No provision has been made for the future costs of terminating the business unless such costs were committed at the reporting date.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Trucs Therapeutics Limited (Registered number: 11749031)

Notes to the Financial Statements - continued
for the year ended 30 June 2024


2. Accounting policies - continued

Foreign exchange
Transactions in currencies other than the functional currency (foreign currency) are initially recorded at the exchange rate prevailing on the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies are translated at the rate ruling at the date of the transaction, or, if the asset or liability is measured at fair value, the rate when that fair value was determined.

All translation differences are taken to profit or loss, except to the extent that they relate to gains or losses on non-monetary items recognised in other comprehensive income, when the related translation gain or loss is also recognised in other comprehensive income.

Financial instruments
Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs.

3. Employees and directors

The average number of employees during the year was NIL (2023 - NIL).

4. Debtors: amounts falling due within one year
2024 2023
$ $
Amounts owed by group undertakings 1,911,680 1,871,754
VAT - 7,576
1,911,680 1,879,330

5. Creditors: amounts falling due within one year
2024 2023
$ $
Trade creditors - 1,971
Tax 1,958 25,313
Accruals and deferred income 24,220 34,801
26,178 62,085

Trucs Therapeutics Limited (Registered number: 11749031)

Notes to the Financial Statements - continued
for the year ended 30 June 2024


6. Called up share capital

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: $ $
100 Ordinary share capital 1 121 121

7. Reserves
Retained
earnings
$

At 1 July 2023 2,268,880
Deficit for the year (55,273 )
At 30 June 2024 2,213,607

8. Disclosure under Section 444(5B) of the Companies Act 2006

The Auditors' Report was unqualified.

Jonathan Moughton (Senior Statutory Auditor)
for and on behalf of Cooper Parry Group Limited

9. Parent company

The ultimate parent company and controlling party is Adaptimmune Therapeutics Plc.